New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

The regulatory filing for the drug did not specify that use should be limited to the ESR1-positive population, so the FDA has approved a narrower label than originally sought when Stemline filed ...

“These data from VERITAC-2 support the potential of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared to fulvestrant.

ESR1 mutations are a common cause of acquired ... The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ...

Targeted therapies for ESR1 mutations or for the PI3K pathway alterations provide additional treatment options, he continued; however, the decision to continue a CDK4/6 inhibitor after progression is ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.